← Leaderboards
Linda M S Resar
Johns Hopkins University
$8,865,484
Attributed
$13,026,950
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,026,950 · 14
By mechanism
R01$10,029,413 · 6
U01$1,311,804 · 1
R21$723,883 · 2
R03$634,610 · 4
R29$327,240 · 1
Top collaborators
- Lewis C Becker4 shared
- Alison R Moliterno4 shared
- Elizabeth Marion Jaffee2 shared
- Shulin Li2 shared
- Lopa Mishra2 shared
- Kirti Shetty2 shared
- Herbert Yu2 shared
- Jerry L Spivak1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Alison R Moliterno$2,465,567
- Youngeun Joseph Kim$146,582
- Aglaia Zellos$0
- Chloe L Thio$13,807,555
- Ariel Larissa Gold$96,668
Others in their field
Top investigators on “Phenotype”
- David R. Weir · University Of Michigan At Ann Arbor$239,033,262
- David Heimbrook · Leidos Biomedical Research, Inc.$213,586,034
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Richard A Gibbs · Baylor College Of Medicine$184,906,270
- James E. Gern · University Of Wisconsin-Madison$141,704,104
- Garret A Fitzgerald · University Of Pennsylvania$141,348,491
Research focus
PhenotypeMouse ModelCellsMalignant NeoplasmsGene ExpressionProteinsTumorPathway InteractionsGenesOverexpressionBaseMolecularChromatinIn VivoInnovationOncogenicTumor ProgressionCessation Of LifeLeadPre-ClinicalStem CellsTissuesChromatin RemodelingPathogenesis
Grant awards (40)
Targeting HMGA1 Tumor-Stromal Networks in Pancreatic Carcinogenesis$437,746
R01 · FY2025 · CA · contact PI
Targeting HMGA1 Tumor-Stromal Networks in Pancreatic Carcinogenesis$431,561
R01 · FY2024 · CA · contact PI
Clonal Hematopoiesis in Healthy Individuals from Families with Early OnsetCoronary Artery Disease$800,523
R01 · FY2022 · HL
High Mobility Group A1 Chromatin Regulators in Colon Carcinogenesis$349,661
R01 · FY2022 · CA · contact PI
High Mobility Group A1 Chromatin Regulators in Colon Carcinogenesis$113,878
R01 · FY2022 · CA · contact PI
Clonal Hematopoiesis in Healthy Individuals from Families with Early OnsetCoronary Artery Disease$806,434
R01 · FY2021 · HL
HMGA Chromatin Remodeling Proteins in Tumor Progression in Myeloproliferative Neoplasms (MPN)$472,224
R01 · FY2021 · HL · contact PI
High Mobility Group A1 Chromatin Regulators in Colon Carcinogenesis$356,797
R01 · FY2021 · CA · contact PI
Clonal Hematopoiesis in Healthy Individuals from Families with Early OnsetCoronary Artery Disease$809,064
R01 · FY2020 · HL
Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer$663,918
U01 · FY2020 · CA
HMGA Chromatin Remodeling Proteins in Tumor Progression in Myeloproliferative Neoplasms (MPN)$477,782
R01 · FY2020 · HL · contact PI
High Mobility Group A1 Chromatin Regulators in Colon Carcinogenesis$356,797
R01 · FY2020 · CA · contact PI
Clonal Hematopoiesis in Healthy Individuals from Families with Early OnsetCoronary Artery Disease$851,405
R01 · FY2019 · HL
Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer$647,886
U01 · FY2019 · CA
HMGA Chromatin Remodeling Proteins in Tumor Progression in Myeloproliferative Neoplasms (MPN)$483,395
R01 · FY2019 · HL · contact PI
High Mobility Group A1 Chromatin Regulators in Colon Carcinogenesis$383,665
R01 · FY2019 · CA · contact PI
The HMGA1 Chromatin Regulator in Hematopoietic Stem Cells with Aging$294,750
R01 · FY2019 · DK · contact PI
HMGA Chromatin Remodeling Proteins in Tumor Progression in Myeloproliferative Neoplasms (MPN)$490,434
R01 · FY2018 · HL · contact PI
High Mobility Group A1 Chromatin Regulators in Colon Carcinogenesis$367,003
R01 · FY2018 · CA · contact PI
The HMGA1 Chromatin Regulator in Hematopoietic Stem Cells with Aging$294,713
R01 · FY2018 · DK · contact PI
The HMGA1 Chromatin Regulator in Hematopoietic Stem Cells with Aging$294,300
R01 · FY2017 · DK · contact PI
Developing a Screen for Novel Therapies with Reprogrammed Pancreatic Cancer Cells$81,000
R03 · FY2016 · CA · contact PI
Developing a Screen for Novel Therapies with Reprogrammed Pancreatic Cancer Cells$81,000
R03 · FY2015 · CA · contact PI
Developing Nanotechnology to Target HMGA1 in Pancreatic Cancer$81,000
R03 · FY2015 · CA · contact PI
Developing Nanotechnology to Target HMGA1 in Pancreatic Cancer$70,470
R03 · FY2014 · CA · contact PI
Targeting the let-7-HMGA2 Network in Metastatic Progression in Pancreatic Cancer$76,140
R03 · FY2013 · CA · contact PI
Targeting the let-7-HMGA2 Network in Metastatic Progression in Pancreatic Cancer$81,000
R03 · FY2012 · CA · contact PI
HMGA1 in Tumor Progression in Breast Cancer$173,000
R21 · FY2011 · CA · contact PI
HMGA1 in Tumor Progression in Breast Cancer$214,020
R21 · FY2010 · CA · contact PI
Targeting HMGA1 in Pancreatic Tumor Progression$82,000
R03 · FY2010 · CA · contact PI
Targeting HMGA1 in Pancreatic Tumor Progression$82,000
R03 · FY2009 · CA · contact PI
The Role of HMG-I/Y in Uterine Cancer$181,538
R21 · FY2007 · CA · contact PI
Mechanisms of Neoplastic Transformation by HMG-I/Y$284,191
R01 · FY2006 · CA · contact PI
The Role of HMG-I/Y in Uterine Cancer$155,325
R21 · FY2006 · CA · contact PI
Mechanisms of Neoplastic Transformation by HMG-I/Y$291,030
R01 · FY2005 · CA
Mechanisms of Neoplastic Transformation by HMG-I/Y$291,030
R01 · FY2004 · CA
Mechanisms of Neoplastic Transformation by HMG-I/Y$291,030
R01 · FY2003 · CA
HMG-1/Y AND NEOPLASTIC TRANSFORMATION$105,930
R29 · FY2002 · CA
HMG-1/Y AND NEOPLASTIC TRANSFORMATION$109,193
R29 · FY2001 · CA
HMG-1/Y AND NEOPLASTIC TRANSFORMATION$112,117
R29 · FY2000 · CA